[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

UY35415A - Proteínas de unión a antígeno. - Google Patents

Proteínas de unión a antígeno.

Info

Publication number
UY35415A
UY35415A UY0001035415A UY35415A UY35415A UY 35415 A UY35415 A UY 35415A UY 0001035415 A UY0001035415 A UY 0001035415A UY 35415 A UY35415 A UY 35415A UY 35415 A UY35415 A UY 35415A
Authority
UY
Uruguay
Prior art keywords
proteins
antigen
union
lag
antigen binding
Prior art date
Application number
UY0001035415A
Other languages
English (en)
Inventor
Paul Andrew Hamblin
Alan Peter Lewis
Thomas Matthew Webb
Original Assignee
Glaxosmithkline Ip Dev Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Ip Dev Ltd filed Critical Glaxosmithkline Ip Dev Ltd
Publication of UY35415A publication Critical patent/UY35415A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Neurology (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente invención se refiere a proteínas de unión a antígeno que se unen al gen de activación de linfocitos 3 (LAG-3) y más particularmente, a proteínas de unión a antígeno que pueden producir reducción de linfocitos T activados LAG-3+.
UY0001035415A 2013-03-15 2014-03-13 Proteínas de unión a antígeno. UY35415A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361789325P 2013-03-15 2013-03-15

Publications (1)

Publication Number Publication Date
UY35415A true UY35415A (es) 2014-10-31

Family

ID=50272641

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001035415A UY35415A (es) 2013-03-15 2014-03-13 Proteínas de unión a antígeno.

Country Status (35)

Country Link
US (6) US10280221B2 (es)
EP (2) EP2970464B1 (es)
JP (3) JP6224739B2 (es)
KR (1) KR101763352B1 (es)
CN (1) CN105209494B (es)
AR (1) AR095432A1 (es)
AU (1) AU2014230741B2 (es)
CA (1) CA2902831C (es)
CL (1) CL2015002517A1 (es)
CR (1) CR20150492A (es)
CY (1) CY1123220T1 (es)
DK (1) DK2970464T3 (es)
DO (1) DOP2015000243A (es)
EA (1) EA037554B1 (es)
ES (1) ES2808654T3 (es)
HK (1) HK1219966A1 (es)
HR (1) HRP20201113T1 (es)
HU (1) HUE049957T2 (es)
IL (1) IL240838B (es)
LT (1) LT2970464T (es)
MA (1) MA38498B1 (es)
ME (1) ME03796B (es)
MX (1) MX351349B (es)
NZ (1) NZ711355A (es)
PE (1) PE20151530A1 (es)
PH (1) PH12015502039A1 (es)
PL (1) PL2970464T3 (es)
PT (1) PT2970464T (es)
RS (1) RS60538B1 (es)
SG (1) SG11201506807RA (es)
SI (1) SI2970464T1 (es)
TW (1) TWI658051B (es)
UA (1) UA118750C2 (es)
UY (1) UY35415A (es)
WO (1) WO2014140180A1 (es)

Families Citing this family (167)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ629913A (en) 2010-08-23 2016-01-29 Univ Texas Anti-ox40 antibodies and methods of using the same
WO2013013188A1 (en) 2011-07-21 2013-01-24 Tolero Pharmaceuticals, Inc. Heterocyclic protein kinase inhibitors
UY34887A (es) 2012-07-02 2013-12-31 Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
AU2014230741B2 (en) 2013-03-15 2017-04-13 Glaxosmithkline Intellectual Property Development Limited Anti-LAG-3 binding proteins
LT3508502T (lt) 2013-09-20 2023-07-10 Bristol-Myers Squibb Company Anti-lag-3 antikūnų ir anti-pd-1 antikūnų derinys, skirtas navikų gydymui
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
TWI693232B (zh) 2014-06-26 2020-05-11 美商宏觀基因股份有限公司 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法
JO3663B1 (ar) 2014-08-19 2020-08-27 Merck Sharp & Dohme الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
MA41463A (fr) * 2015-02-03 2017-12-12 Anaptysbio Inc Anticorps dirigés contre le gène d'activation 3 des lymphocytes (lag-3)
SI3303394T1 (sl) 2015-05-29 2020-10-30 Agenus Inc. Protitelesa proti-CTLA-4 in postopki njihove uporabe
TWI773646B (zh) 2015-06-08 2022-08-11 美商宏觀基因股份有限公司 結合lag-3的分子和其使用方法
MX2017016844A (es) 2015-07-16 2018-08-15 Biokine Therapeutics Ltd Composiciones y procedimientos para tratar cancer.
CN107847574B (zh) 2015-07-30 2023-05-23 宏观基因有限公司 Pd-1结合分子和其使用方法
EP3344654B1 (en) * 2015-09-02 2020-10-21 Immutep S.A.S. Anti-lag-3 antibodies
KR102431342B1 (ko) 2015-10-02 2022-08-10 에프. 호프만-라 로슈 아게 Pd1 및 tim3에 특이적인 이중특이성 항체
TWI756187B (zh) * 2015-10-09 2022-03-01 美商再生元醫藥公司 抗ｌａｇ３抗體及其用途
JP6945456B2 (ja) * 2015-11-13 2021-10-06 マクロジェニクス，インコーポレーテッド Ｌａｇ‐３結合分子及びその使用方法
WO2017087901A2 (en) * 2015-11-19 2017-05-26 Sutro Biopharma, Inc. Anti-lag3 antibodies, compositions comprising anti-lag3 antibodies and methods of making and using anti-lag3 antibodies
EA201891178A1 (ru) 2015-12-14 2019-01-31 Макродженикс, Инк. Биспецифичные молекулы, обладающие иммунореактивностью в отношении pd-1 и ctla-4, и способы их применения
JP7000322B2 (ja) 2015-12-16 2022-02-04 メルク・シャープ・アンド・ドーム・コーポレーション 抗ｌａｇ３抗体および抗原結合性フラグメント
SG10201601719RA (en) * 2016-03-04 2017-10-30 Agency Science Tech & Res Anti-LAG-3 Antibodies
SI3458478T1 (sl) 2016-05-18 2021-04-30 Boehringer Ingelheim International Gmbh Anti-PD1 in anti-LAG3 protitelesa za zdravljenje raka
US11472856B2 (en) 2016-06-13 2022-10-18 Torque Therapeutics, Inc. Methods and compositions for promoting immune cell function
WO2017220555A1 (en) 2016-06-20 2017-12-28 F-Star Beta Limited Lag -3 binding members
CA3026477A1 (en) 2016-06-20 2017-12-28 Kymab Limited Anti-pd-l1 antibodies
PT3472207T (pt) 2016-06-20 2021-03-31 F Star Delta Ltd Moléculas ligantes que se ligam a pd-l1 e lag-3
CA3024359A1 (en) * 2016-06-23 2017-12-28 Jiangsu Hengrui Medicine Co., Ltd. Lag-3 antibody, antigen-binding fragment thereof, and pharmaceutical application thereof
GB201612520D0 (en) 2016-07-19 2016-08-31 F-Star Beta Ltd Binding molecules
EA039718B1 (ru) * 2016-07-21 2022-03-03 Регенерон Фармасьютикалз, Инк. Антитела к lag3 и их применения
MX2019001878A (es) 2016-08-17 2019-07-01 Compugen Ltd Anticuerpos anti-tigit, anticuerpos anti-pvrig y combinaciones de estos.
SG10201912764TA (en) * 2016-09-08 2020-02-27 Daiichi Sankyo Co Ltd Antibody for treating autoimmune diseases
MX2019003683A (es) 2016-10-11 2019-08-22 Agenus Inc Anticuerpos anti gen 3 de activación linfocítica (lag 3 ) y métodos para usarlos.
PE20190911A1 (es) * 2016-10-13 2019-06-26 Symphogen As Composiciones y anticuerpos anti-lag-3
US11279694B2 (en) 2016-11-18 2022-03-22 Sumitomo Dainippon Pharma Oncology, Inc. Alvocidib prodrugs and their use as protein kinase inhibitors
MX2019006340A (es) 2016-12-07 2019-11-07 Agenus Inc Anticuerpos anti antígeno 4 del linfocito t citotóxico (ctla-4) y métodos de uso de los mismos.
AU2018219909A1 (en) 2017-02-10 2019-09-12 Regeneron Pharmaceuticals, Inc. Radiolabeled anti-LAG3 antibodies for immuno-PET imaging
US10577421B2 (en) * 2017-02-22 2020-03-03 I-Mab Anti-LAG-3 antibodies and uses thereof
MY201482A (en) 2017-04-03 2024-02-26 Hoffmann La Roche Immunoconjugates of an anti-pd-1 antibody with a mutant il-2 or with il-15
EP4230654A1 (en) 2017-04-05 2023-08-23 Symphogen A/S Combination therapies targeting pd-1, tim-3, and lag-3
HRP20221141T1 (hr) 2017-04-05 2022-11-25 F. Hoffmann - La Roche Ag Anti-lag3 protutijela
JP6997212B2 (ja) 2017-04-05 2022-02-04 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Ｐｄ１及びｌａｇ３に特異的に結合する二重特異性抗体
MX2019012793A (es) * 2017-04-27 2020-02-13 Tesaro Inc Agentes anticuerpos dirigidos contra el gen de activación de linfocitos-3 (lag-3) y usos de los mismos.
AR111651A1 (es) 2017-04-28 2019-08-07 Novartis Ag Conjugados de anticuerpos que comprenden agonistas del receptor de tipo toll y terapias de combinación
BR112019018759A2 (pt) 2017-05-30 2020-05-05 Bristol-Myers Squibb Company composições compreendendo uma combinação de um anticorpo anti-lag-3, um inibidor da via pd-1, e um agente imunoterápico
LT3631454T (lt) 2017-05-30 2023-11-27 Bristol-Myers Squibb Company Lag-3 atžvilgiu teigiamų navikų gydymas
BR112019021847A2 (pt) 2017-05-30 2020-06-02 Bristol-Myers Squibb Company Composições compreendendo um anticorpo anti-lag-3 ou um anticorpo anti-lag-3 e um anticorpo anti-pd-1 ou anti-pd-l1
WO2018229715A1 (en) 2017-06-16 2018-12-20 Novartis Ag Compositions comprising anti-cd32b antibodies and methods of use thereof
WO2018235056A1 (en) 2017-06-22 2018-12-27 Novartis Ag IL-1BETA BINDING ANTIBODIES FOR USE IN THE TREATMENT OF CANCER
CA3061874A1 (en) 2017-06-22 2018-12-27 Novartis Ag Il-1beta binding antibodies for use in treating cancer
CA3066774A1 (en) 2017-06-22 2018-12-27 Novartis Ag Antibody molecules to cd73 and uses thereof
MX2019015738A (es) 2017-06-27 2020-02-20 Novartis Ag Regimen de dosificacion para anticuerpos anti-tim-3 y usos de los mismos.
EP3652212A4 (en) * 2017-07-13 2021-04-14 Nanjing Leads Biolabs Co., Ltd. LAG-3 BINDING ANTIBODIES AND USES THEREOF
US20200172617A1 (en) 2017-07-20 2020-06-04 Novartis Ag Dosage regimens of anti-lag-3 antibodies and uses thereof
IL272697B2 (en) 2017-08-18 2023-12-01 Adastra Pharmaceuticals Inc A polymorphic form of TG02
JP2020536495A (ja) * 2017-08-30 2020-12-17 フェインズ セラピューティクス，インコーポレーテッド 抗ｌａｇ−３抗体及びその使用
JP7196160B2 (ja) 2017-09-12 2022-12-26 スミトモ ファーマ オンコロジー， インコーポレイテッド Ｍｃｌ－１阻害剤アルボシジブを用いた、ｂｃｌ－２阻害剤に対して非感受性である癌の治療レジメン
WO2019070013A1 (ja) 2017-10-05 2019-04-11 第一三共株式会社 細胞傷害性ｔ細胞枯渇用組成物
WO2019081983A1 (en) 2017-10-25 2019-05-02 Novartis Ag CD32B TARGETING ANTIBODIES AND METHODS OF USE
MX2020004756A (es) 2017-11-16 2020-08-20 Novartis Ag Terapias de combinacion.
TW201925782A (zh) 2017-11-30 2019-07-01 瑞士商諾華公司 靶向bcma之嵌合抗原受體及其用途
EP3728316A1 (en) 2017-12-19 2020-10-28 F-Star Beta Limited Fc binding fragments comprising a pd-l1 antigen-binding site
AU2018391217A1 (en) 2017-12-22 2020-07-09 Jiangsu Hengrui Medicine Co., Ltd. LAG-3 antibody pharmaceutical composition and use thereof
CN109970856B (zh) 2017-12-27 2022-08-23 信达生物制药(苏州)有限公司 抗lag-3抗体及其用途
TW201930591A (zh) 2018-01-08 2019-08-01 瑞士商諾華公司 用於與嵌合抗原受體療法併用之免疫增強rna
WO2019152660A1 (en) 2018-01-31 2019-08-08 Novartis Ag Combination therapy using a chimeric antigen receptor
JP2021511793A (ja) 2018-01-31 2021-05-13 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト Ｌａｇ３に結合する抗原結合部位を含む二重特異性抗体
US20200399383A1 (en) 2018-02-13 2020-12-24 Novartis Ag Chimeric antigen receptor therapy in combination with il-15r and il15
EP3768720A4 (en) 2018-03-20 2022-01-05 Wuxi Biologics Ireland Limited NEW ANTI-LAG-3 ANTIBODY POLYPEPTIDE
WO2019192432A1 (zh) 2018-04-02 2019-10-10 上海博威生物医药有限公司 结合淋巴细胞活化基因-3(lag-3)的抗体及其用途
US20210147547A1 (en) 2018-04-13 2021-05-20 Novartis Ag Dosage Regimens For Anti-Pd-L1 Antibodies And Uses Thereof
TW202015726A (zh) 2018-05-30 2020-05-01 瑞士商諾華公司 Ｅｎｔｐｄ２抗體、組合療法、及使用該等抗體和組合療法之方法
WO2019232244A2 (en) 2018-05-31 2019-12-05 Novartis Ag Antibody molecules to cd73 and uses thereof
CR20200571A (es) 2018-06-01 2021-01-18 Novartis Ag Moléculas de únion contra bcma y usos de las mismas
CN110615840A (zh) * 2018-06-19 2019-12-27 信达生物制药(苏州)有限公司 全人源的抗lag-3抗体及其应用
AR116109A1 (es) 2018-07-10 2021-03-31 Novartis Ag Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
CN112261970A (zh) 2018-07-10 2021-01-22 诺华股份有限公司 3-(5-羟基-1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物及其在治疗ikaros家族锌指2(ikzf2)依赖性疾病中的用途
GB201811408D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd CD137 Binding Molecules
WO2020021465A1 (en) 2018-07-25 2020-01-30 Advanced Accelerator Applications (Italy) S.R.L. Method of treatment of neuroendocrine tumors
EP3826660A1 (en) 2018-07-26 2021-06-02 Bristol-Myers Squibb Company Lag-3 combination therapy for the treatment of cancer
SG11202102864XA (en) 2018-10-19 2021-05-28 Bristol Myers Squibb Co Combination therapy for melanoma
US20230053449A1 (en) 2018-10-31 2023-02-23 Novartis Ag Dc-sign antibody drug conjugates
CN113490499A (zh) 2018-12-04 2021-10-08 大日本住友制药肿瘤公司 用作治疗癌症的活性剂的cdk9抑制剂及其多晶型物
KR20210106437A (ko) 2018-12-20 2021-08-30 노파르티스 아게 3-(1-옥소이소인돌린-2-일)피페리딘-2,6-디온 유도체를 포함하는 투약 요법 및 약학적 조합물
WO2020128613A1 (en) 2018-12-21 2020-06-25 Novartis Ag Use of il-1beta binding antibodies
US20220056123A1 (en) 2018-12-21 2022-02-24 Novartis Ag Use of il-1beta binding antibodies
WO2020127965A1 (en) 2018-12-21 2020-06-25 Onxeo New conjugated nucleic acid molecules and their uses
SG11202104699TA (en) 2018-12-21 2021-07-29 Novartis Ag Use of il-1 beta antibodies in the treatment or prevention of myelodysplastic syndrome
WO2020128637A1 (en) 2018-12-21 2020-06-25 Novartis Ag Use of il-1 binding antibodies in the treatment of a msi-h cancer
US11471456B2 (en) 2019-02-12 2022-10-18 Sumitomo Pharma Oncology, Inc. Formulations comprising heterocyclic protein kinase inhibitors
US20220144798A1 (en) 2019-02-15 2022-05-12 Novartis Ag Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
JP7483732B2 (ja) 2019-02-15 2024-05-15 ノバルティス アーゲー ３－（１－オキソ－５－（ピペリジン－４－イル）イソインドリン－２－イル）ピペリジン－２，６－ジオン誘導体及びその使用
WO2020180424A1 (en) 2019-03-04 2020-09-10 Iocurrents, Inc. Data compression and communication using machine learning
US11793802B2 (en) 2019-03-20 2023-10-24 Sumitomo Pharma Oncology, Inc. Treatment of acute myeloid leukemia (AML) with venetoclax failure
WO2020198077A1 (en) 2019-03-22 2020-10-01 Sumitomo Dainippon Pharma Oncology, Inc. Compositions comprising pkm2 modulators and methods of treatment using the same
SG11202110449YA (en) 2019-03-26 2021-10-28 Univ Michigan Regents Small molecule degraders of stat3
US20220185831A1 (en) 2019-03-29 2022-06-16 The Regents Of The University Of Michigan Stat3 protein degraders
US20220134727A1 (en) 2019-03-29 2022-05-05 Nitto Denko Corporation Method for manufacturing laminate, method for manufacturing coated article, method for manufacturing bonded structure, thermal transfer sheet, and laminate
CN113825527A (zh) 2019-05-13 2021-12-21 瑞泽恩制药公司 用于在治疗癌症中增强效力的pd-1抑制剂和lag-3抑制剂的组合
JP2022534981A (ja) 2019-05-30 2022-08-04 ブリストル－マイヤーズ スクイブ カンパニー 細胞局在化シグネチャーおよび組み合わせ治療
KR20220016155A (ko) 2019-05-30 2022-02-08 브리스톨-마이어스 스큅 컴퍼니 면역-종양학 (i-o) 요법에 적합한 대상체를 확인하는 방법
CN114174538A (zh) 2019-05-30 2022-03-11 百时美施贵宝公司 适合于免疫肿瘤学疗法的多肿瘤基因特征
CN112010972B (zh) * 2019-05-31 2023-01-10 瑞阳(苏州)生物科技有限公司 与人lag-3蛋白结合的抗体及其编码基因和应用
EP3984554A4 (en) * 2019-06-11 2023-11-08 ONO Pharmaceutical Co., Ltd. IMMUNOSUPPRESSION AGENT
WO2020252353A1 (en) 2019-06-12 2020-12-17 Vanderbilt University Amino acid transport inhibitors and the uses thereof
CN114269715A (zh) 2019-06-12 2022-04-01 范德比尔特大学 作为氨基酸转运抑制剂的二苄基胺
EP3994132A1 (en) 2019-07-03 2022-05-11 Sumitomo Dainippon Pharma Oncology, Inc. Tyrosine kinase non-receptor 1 (tnk1) inhibitors and uses thereof
MX2022000550A (es) 2019-07-16 2022-02-10 Univ Michigan Regents Imidazopirimidinas como inhibidores de eed y uso de estas.
WO2021024020A1 (en) 2019-08-06 2021-02-11 Astellas Pharma Inc. Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer
CA3151824A1 (en) 2019-08-27 2021-03-04 The Regents Of The University Of Michigan Cereblon e3 ligase inhibitors
JP2022548881A (ja) 2019-09-18 2022-11-22 ノバルティス アーゲー Ｅｎｔｐｄ２抗体、組合せ療法並びに抗体及び組合せ療法を使用する方法
US20220380368A1 (en) 2019-09-19 2022-12-01 The Regents Of The University Of Michigan Spirocyclic androgen receptor protein degraders
WO2021055994A1 (en) 2019-09-22 2021-03-25 Bristol-Myers Squibb Company Quantitative spatial profiling for lag-3 antagonist therapy
CN114786679A (zh) 2019-10-21 2022-07-22 诺华股份有限公司 具有维奈托克和tim-3抑制剂的组合疗法
EP4048285A1 (en) 2019-10-21 2022-08-31 Novartis AG Tim-3 inhibitors and uses thereof
WO2021092220A1 (en) 2019-11-06 2021-05-14 Bristol-Myers Squibb Company Methods of identifying a subject with a tumor suitable for a checkpoint inhibitor therapy
WO2021092221A1 (en) 2019-11-06 2021-05-14 Bristol-Myers Squibb Company Methods of identifying a subject with a tumor suitable for a checkpoint inhibitor therapy
US20220411499A1 (en) 2019-11-08 2022-12-29 Bristol-Myers Squibb Company LAG-3 Antagonist Therapy for Melanoma
EP4077389A1 (en) 2019-12-20 2022-10-26 Novartis AG Combination of anti tim-3 antibody mbg453 and anti tgf-beta antibody nis793, with or without decitabine or the anti pd-1 antibody spartalizumab, for treating myelofibrosis and myelodysplastic syndrome
JP2023510393A (ja) 2020-01-17 2023-03-13 ノバルティス アーゲー 骨髄異形成症候群または慢性骨髄単球性白血病の処置に使用するためのｔｉｍ－３阻害剤と低メチル化剤とを含む組合せ
US20230087600A1 (en) 2020-02-06 2023-03-23 Bristol-Myers Squibb Company Il-10 and uses thereof
US20230159573A1 (en) 2020-03-26 2023-05-25 The Regents Of The University Of Michigan Small molecule stat protein degraders
TW202214857A (zh) 2020-06-19 2022-04-16 法商昂席歐公司 新型結合核酸分子及其用途
BR112022026202A2 (pt) 2020-06-23 2023-01-17 Novartis Ag Regime de dosagem compreendendo derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona
IL298993A (en) 2020-07-07 2023-02-01 BioNTech SE Therapeutic RNA for HPV positive cancer
US20230257365A1 (en) 2020-07-10 2023-08-17 The Regents Of The University Of Michigan Small molecule androgen receptor protein degraders
US20230233690A1 (en) 2020-07-10 2023-07-27 The Regents Of The University Of Michigan Androgen receptor protein degraders
EP4188549A1 (en) 2020-08-03 2023-06-07 Novartis AG Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
EP4204095A1 (en) 2020-08-28 2023-07-05 Bristol-Myers Squibb Company Lag-3 antagonist therapy for hepatocellular carcinoma
EP4204020A1 (en) 2020-08-31 2023-07-05 Advanced Accelerator Applications International S.A. Method of treating psma-expressing cancers
EP4204021A1 (en) 2020-08-31 2023-07-05 Advanced Accelerator Applications International S.A. Method of treating psma-expressing cancers
CA3190660A1 (en) 2020-08-31 2022-03-03 George C. Lee Cell localization signature and immunotherapy
US20240101666A1 (en) 2020-10-23 2024-03-28 Bristol-Myers Squibb Company Lag-3 antagonist therapy for lung cancer
CA3199095A1 (en) 2020-11-06 2022-05-12 Novartis Ag Cd19 binding molecules and uses thereof
WO2022117572A2 (en) 2020-12-02 2022-06-09 Oncurious Nv An ltbr agonist in combination therapy against cancer
WO2022120179A1 (en) 2020-12-03 2022-06-09 Bristol-Myers Squibb Company Multi-tumor gene signatures and uses thereof
KR20220082558A (ko) 2020-12-10 2022-06-17 재단법인 의약바이오컨버젼스연구단 면역 증진 활성이 있는 신규 crs 단편 펩타이드 및 이의 용도
TW202237119A (zh) 2020-12-10 2022-10-01 美商住友製藥腫瘤公司 Ａｌｋ﹘５抑制劑和彼之用途
TW202245808A (zh) 2020-12-21 2022-12-01 德商拜恩迪克公司 用於治療癌症之治療性ｒｎａ
WO2022135666A1 (en) 2020-12-21 2022-06-30 BioNTech SE Treatment schedule for cytokine proteins
WO2022135667A1 (en) 2020-12-21 2022-06-30 BioNTech SE Therapeutic rna for treating cancer
EP4267105A1 (en) 2020-12-28 2023-11-01 Bristol-Myers Squibb Company Antibody compositions and methods of use thereof
EP4267172A1 (en) 2020-12-28 2023-11-01 Bristol-Myers Squibb Company Subcutaneous administration of pd1/pd-l1 antibodies
WO2022187423A1 (en) 2021-03-03 2022-09-09 The Regents Of The University Of Michigan Cereblon ligands
WO2022187419A1 (en) 2021-03-03 2022-09-09 The Regents Of The University Of Michigan Small molecule degraders of androgen receptor
KR20240005700A (ko) 2021-03-29 2024-01-12 주노 쎄러퓨티크스 인코퍼레이티드 체크포인트 억제제 요법 및 car t 세포 요법의 조합을 사용한 투여 및 치료 방법
TW202304979A (zh) 2021-04-07 2023-02-01 瑞士商諾華公司 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
TW202309022A (zh) 2021-04-13 2023-03-01 美商努法倫特公司 用於治療具egfr突變之癌症之胺基取代雜環
EP4337694A1 (en) 2021-05-12 2024-03-20 Dana-Farber Cancer Institute, Inc. Lag3 and gal3 inhibitory agents, xbp1, cs1, and cd138 peptides, and methods of use thereof
AR125874A1 (es) 2021-05-18 2023-08-23 Novartis Ag Terapias de combinación
KR20240046323A (ko) 2021-07-13 2024-04-08 비온테크 에스이 암에 대한 병용 요법에 있어서 cd40 및 cd137에 대한 다중특이 결합제
TW202333802A (zh) 2021-10-11 2023-09-01 德商拜恩迪克公司 用於肺癌之治療性rna(二)
CA3224890A1 (en) 2021-10-29 2023-05-04 Bristol-Myers Squibb Company Lag-3 antagonist therapy for hematological cancer
CA3240558A1 (en) 2021-12-16 2023-06-22 Valerio Therapeutics New conjugated nucleic acid molecules and their uses
IL314050A (en) 2022-01-26 2024-09-01 Bristol Myers Squibb Co Combined treatment method for hepatocellular carcinoma
IL314713A (en) 2022-02-25 2024-10-01 Bristol Myers Squibb Co Combined therapy for colorectal carcinoma
WO2023168404A1 (en) 2022-03-04 2023-09-07 Bristol-Myers Squibb Company Methods of treating a tumor
AU2023230110A1 (en) 2022-03-08 2024-10-24 Alentis Therapeutics Ag Use of anti-claudin-1 antibodies to increase t cell availability
WO2023178192A1 (en) 2022-03-15 2023-09-21 Compugen Ltd. Il-18bp antagonist antibodies and their use in monotherapy and combination therapy in the treatment of cancer
WO2023178329A1 (en) 2022-03-18 2023-09-21 Bristol-Myers Squibb Company Methods of isolating polypeptides
WO2023214325A1 (en) 2022-05-05 2023-11-09 Novartis Ag Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors
WO2023235847A1 (en) 2022-06-02 2023-12-07 Bristol-Myers Squibb Company Antibody compositions and methods of use thereof
WO2024116140A1 (en) 2022-12-01 2024-06-06 Medimmune Limited Combination therapy for treatment of cancer comprising anti-pd-l1 and anti-cd73 antibodies
WO2024126457A1 (en) 2022-12-14 2024-06-20 Astellas Pharma Europe Bv Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and immune checkpoint inhibitors
WO2024137776A1 (en) 2022-12-21 2024-06-27 Bristol-Myers Squibb Company Combination therapy for lung cancer
US20240299601A1 (en) 2023-02-17 2024-09-12 Regeneron Pharmaceuticals, Inc. Radiolabeled anti-lag3 antibodies for immuno-pet imaging
WO2024192033A1 (en) 2023-03-13 2024-09-19 Regeneron Pharmaceuticals, Inc. Combination of pd-1 inhibitors and lag-3 inhibitors for enhanced efficacy in treating melanoma
WO2024196952A1 (en) 2023-03-20 2024-09-26 Bristol-Myers Squibb Company Tumor subtype assessment for cancer therapy

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57106673A (en) 1980-12-24 1982-07-02 Chugai Pharmaceut Co Ltd Dibenzo(b,f)(1,4)oxazepin derivative
US4666884A (en) 1984-04-10 1987-05-19 New England Deaconess Hospital Method of inhibiting binding of von Willebrand factor to human platelets and inducing interaction of platelets with vessel walls
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
US5976877A (en) 1990-01-08 1999-11-02 Institut National De La Sante Et De La Recherche Medicale (Inserm) Proteins produced by human lymphocytes DNA sequence encoding these proteins and their pharmaceutical and biological uses
WO1991014438A1 (en) 1990-03-20 1991-10-03 The Trustees Of Columbia University In The City Of New York Chimeric antibodies with receptor binding ligands in place of their constant region
GB9424449D0 (en) 1994-12-02 1995-01-18 Wellcome Found Antibodies
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
US5747035A (en) 1995-04-14 1998-05-05 Genentech, Inc. Polypeptides with increased half-life for use in treating disorders involving the LFA-1 receptor
IL122832A (en) 1995-07-21 2006-08-20 Inst Nat Sante Rech Med Methods for detecting, identifying , isolating and selectively labeling and targeting th1 lymphocytes by means of the lag-3 protein
WO1997035614A1 (en) 1996-03-27 1997-10-02 Crc For Biopharmaceutical Research Pty. Ltd. The use of antibodies against cd48 for the treatment of t and b cell lymphomas and leukemias
WO1997043316A1 (en) 1996-05-10 1997-11-20 Beth Israel Deaconess Medical Center, Inc. Physiologically active molecules with extended half-lives and methods of using same
CA2305350C (en) 1997-09-23 2015-04-07 Bundesrepublik Deutschland Letztvertreten Durch Den Direktor Des Robert-Koch-Instituts Costimulating polypeptide of t cells, monoclonal antibodies, and the preparation and use thereof
HUP0100813A3 (en) 1998-02-25 2003-08-28 Lexigen Pharmaceuticals Corp L Enhancing the circulating half-life of antibody-based fusion proteins
GB9809839D0 (en) 1998-05-09 1998-07-08 Glaxo Group Ltd Antibody
US20020142374A1 (en) 1998-08-17 2002-10-03 Michael Gallo Generation of modified molecules with increased serum half-lives
HUP0104865A3 (en) 1999-01-15 2004-07-28 Genentech Inc Polypeptide variants with altered effector function
JP4368530B2 (ja) 1999-04-09 2009-11-18 協和発酵キリン株式会社 免疫機能分子の活性を調節する方法
JP4210454B2 (ja) 2001-03-27 2009-01-21 日本たばこ産業株式会社 炎症性腸疾患治療剤
CA2388245C (en) 1999-10-19 2012-01-10 Tatsuya Ogawa The use of serum-free adapted rat cells for producing heterologous polypeptides
JP3597140B2 (ja) 2000-05-18 2004-12-02 日本たばこ産業株式会社 副刺激伝達分子ａｉｌｉｍに対するヒトモノクローナル抗体及びその医薬用途
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US6374470B1 (en) 2000-10-06 2002-04-23 Milliken & Company Face plate for spun-like textured yarn
ES2649037T3 (es) 2000-12-12 2018-01-09 Medimmune, Llc Moléculas con semividas prolongadas, composiciones y usos de las mismas
US20050089932A1 (en) 2001-04-26 2005-04-28 Avidia Research Institute Novel proteins with targeted binding
US20050053973A1 (en) 2001-04-26 2005-03-10 Avidia Research Institute Novel proteins with targeted binding
CN1555411A (zh) 2001-08-03 2004-12-15 ���迨�����＼���ɷݹ�˾ 抗体-依赖性细胞毒性增大的抗体糖基化变体
US20080108560A1 (en) 2002-03-05 2008-05-08 Eli Lilly And Company Heterologous G-Csf Fusion Proteins
US9321832B2 (en) 2002-06-28 2016-04-26 Domantis Limited Ligand
ES2439580T3 (es) 2003-02-28 2014-01-23 The Johns Hopkins University Regulación de células T
DK1639011T3 (da) 2003-06-30 2009-02-16 Domantis Ltd Pegylerede enkelt-domæne antistoffer (dAb)
CA2543360A1 (en) 2003-10-24 2005-05-06 Joost A. Kolkman Ldl receptor class a and egf domain monomers and multimers
CA2554089C (en) 2004-02-09 2013-10-22 Human Genome Sciences, Inc. Albumin fusion proteins
CA2562764A1 (en) 2004-04-23 2005-11-03 Richard Kroczek Method for the treatment of t cell mediated conditions by depletion of icos-positive cells in vivo
AU2005269759A1 (en) 2004-07-21 2006-02-09 Glycofi, Inc. Immunoglobulins comprising predominantly a GlcNAc2Man3GlcNAc2 glycoform
MX2007000748A (es) 2004-07-22 2007-03-28 Genentech Inc Metodos para tratar el sindrome de sjogren.
US7923538B2 (en) 2005-07-22 2011-04-12 Kyowa Hakko Kirin Co., Ltd Recombinant antibody composition
KR101318611B1 (ko) 2005-07-22 2013-11-13 교와 핫꼬 기린 가부시키가이샤 유전자 재조합 항체 조성물
US9244059B2 (en) 2007-04-30 2016-01-26 Immutep Parc Club Orsay Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
EP1987839A1 (en) * 2007-04-30 2008-11-05 I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
US9585957B2 (en) * 2007-09-07 2017-03-07 The Johns Hopkins University Adenosine receptor agonists and antagonists to modulate T cell responses
AR072999A1 (es) * 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
UY34887A (es) * 2012-07-02 2013-12-31 Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
AU2014230741B2 (en) 2013-03-15 2017-04-13 Glaxosmithkline Intellectual Property Development Limited Anti-LAG-3 binding proteins

Also Published As

Publication number Publication date
DK2970464T3 (da) 2020-08-03
PH12015502039B1 (en) 2016-01-18
CL2015002517A1 (es) 2016-07-08
MX2015012987A (es) 2015-12-15
SI2970464T1 (sl) 2020-08-31
RS60538B1 (sr) 2020-08-31
US20140286935A1 (en) 2014-09-25
CN105209494B (zh) 2019-04-09
HK1219966A1 (zh) 2017-04-21
US20230295295A1 (en) 2023-09-21
SG11201506807RA (en) 2015-09-29
KR20150128879A (ko) 2015-11-18
US20190382482A1 (en) 2019-12-19
DOP2015000243A (es) 2015-12-31
US10344088B2 (en) 2019-07-09
MA38498A1 (fr) 2017-07-31
TW201525000A (zh) 2015-07-01
CN105209494A (zh) 2015-12-30
EA037554B1 (ru) 2021-04-13
NZ711355A (en) 2020-06-26
US20190276535A1 (en) 2019-09-12
IL240838B (en) 2022-09-01
EP2970464A1 (en) 2016-01-20
JP2016516681A (ja) 2016-06-09
US20230242642A1 (en) 2023-08-03
IL240838A0 (en) 2015-10-29
WO2014140180A1 (en) 2014-09-18
AU2014230741A1 (en) 2015-10-08
LT2970464T (lt) 2020-08-25
MX351349B (es) 2017-10-11
CA2902831A1 (en) 2014-09-18
UA118750C2 (uk) 2019-03-11
PH12015502039A1 (en) 2016-01-18
EP2970464B1 (en) 2020-05-06
BR112015022593A2 (pt) 2017-10-24
US10280221B2 (en) 2019-05-07
KR101763352B1 (ko) 2017-07-31
JP2018007668A (ja) 2018-01-18
CY1123220T1 (el) 2021-10-29
JP2019068826A (ja) 2019-05-09
AR095432A1 (es) 2015-10-14
TWI658051B (zh) 2019-05-01
HUE049957T2 (hu) 2020-11-30
ME03796B (me) 2021-04-20
EP3712177A1 (en) 2020-09-23
HRP20201113T1 (hr) 2020-10-30
JP6833798B2 (ja) 2021-02-24
ES2808654T3 (es) 2021-03-01
PT2970464T (pt) 2020-08-05
EA201591467A1 (ru) 2016-04-29
MA38498B1 (fr) 2018-11-30
CA2902831C (en) 2023-04-25
PL2970464T3 (pl) 2020-10-05
PE20151530A1 (es) 2015-11-06
US20160017037A1 (en) 2016-01-21
AU2014230741B2 (en) 2017-04-13
JP6224739B2 (ja) 2017-11-01
CR20150492A (es) 2015-11-20

Similar Documents

Publication Publication Date Title
UY35415A (es) Proteínas de unión a antígeno.
CY2022035I2 (el) Βελτιστοποιηση αντισωματων που δεσμευουν το γονιδιο-3 ενεργοποιησης λεμφοκυτταρων (lag-3), και χρησεις εξ' αυτων
CL2017002752A1 (es) Anticuerpos heterodiméricos que unen anticuerpos cd3 y tumorales
CY1123236T1 (el) Αντισωματα διπλης εξειδικευσης που δεσμευονται με cd38 και cd3
CY1124993T1 (el) Ετεροδιμερικα αντισωματα που δεσμευουν cd3 και cd20
CL2017001361A1 (es) Anticuerpos heterodiméricos que se unen a cd3 y cd38
CL2016000460A1 (es) Proteínas de unión al antígeno gitr
CR20140585A (es) Proteinas de union a antigeno st2
CY1121862T1 (el) Αντισωματα anti-phf-tau και χρησεις αυτων
BR112017004614A2 (pt) terapias de combinação com anticorpos anti-cd38
BR112017023872A2 (pt) anticorpos anti-cd166, anticorpos anti-cd166 ativáveis e métodos de uso dos mesmos
BR112016000903A2 (pt) anticorpos
CL2015002756A1 (es) Moléculas fc biespecíficas
CL2015002742A1 (es) Moléculas de unión para bcma y cd3.
BR112018071276A2 (pt) anticorpos anti-il-33, composições, métodos e usos dos mesmos
BR112017027724A2 (pt) terapias de combinação para malignidades hematológicas com anticorpos anti-cd38 e inibidores de survivina
BR112015022978A8 (pt) tecnologias de multimerização
EA201691266A1 (ru) Анти-cd3 антитела и способы применения
EA201690314A1 (ru) Анти-garp-белок и его применения
TR201905458T4 (tr) Fap ve dr5 için spesifik bispesifik antikorlar, dr5 için spesifik antikorlar ve bunların kullanım yöntemleri.
CU20170012A7 (es) Anticuerpos anti proteína similar a angiopoyetina 4
MA40663A1 (fr) Anticorps hétérodimériques se liant aux antigènes cd3 et cd38
MA39405A1 (fr) Anticorps bispécifiques se liant à cd38 et cd3
TR201011179A2 (tr) Bir akıllı yönlendirme sistemi ve yöntemi.

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20221219